701295-52-5Relevant academic research and scientific papers
Transition-metal-free alkynylation of aryl chlorides
Truong, Thanh,Daugulis, Olafs
supporting information; experimental part, p. 4172 - 4175 (2011/10/02)
Two sets of conditions have been developed for a base-mediated, transition-metal-free alkynylation of aryl chlorides that proceeds via benzyne intermediates. The first set of conditions involves the use of TMPLi base in a pentane/THF mixture at 25 °C. The
2,2'-diamino-6,6'-dimethylbiphenyl as an efficient ligand in the CuI-catalyzed sonogashira reaction of aryl iodides and bromides with terminal alkynes
Wang, Bin-Bin,Ye, Yue-Mei,Chen, Jun-Jun,Zhou, Xia-Xia,Lu, Jian-Mei,Shao, Li-Xiong
experimental part, p. 526 - 530 (2011/06/25)
2,2'-Diamino-6,6'-dimethylbiphenyl (L1) was found to be a good ligand in the CuI-catalyzed Sonogashira coupling reaction of various aryl iodides and bromides with terminal alkynes. Under suitable conditions, all reactions gave the desired coupling product
Macrocyclic hepatitis C serine protease inhibitors
-
Page/Page column 143, (2008/06/13)
The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
